Abstract: Methods of diagnosing celiac disease in a subject are provided. In some embodiments, the method comprises contacting a sample of bodily fluid from the subject with an antigen comprising a recombinant or synthetic deamidated gliadin protein, wherein the deamidated gliadin protein comprises a hexamer of peptides each having the sequence of SEQ ID NO:1; and detecting an antibody from the sample that specifically binds to the antigen, thereby diagnosing celiac disease in the subject.

Abstract: Methods of diagnosing celiac disease in a subject are provided. In some embodiments, the method comprises contacting a sample of bodily fluid from the subject with an antigen comprising a recombinant or synthetic deamidated gliadin protein, wherein the deamidated gliadin protein comprises a hexamer of peptides each having the sequence of SEQ ID NO:1; and detecting an antibody from the sample that specifically binds to the antigen, thereby diagnosing celiac disease in the subject.

Abstract: The present invention provides a method for determining whether a subject is suffering from celiac disease by contacting a sample of bodily fluid from the subject, with an antigen formed from a hexamer of a gliadin fusion protein immobilized on a solid support. The gliadin fusion protein of the antigen includes a recombinant deamidated gliadin linked to a tag such as Glutathione-S transferase (GST) protein. The antigen is prepared by immobilizing the gliadin fusion protein on the solid support. The antigen can further include tissue Transglutaminase (tTG) cross-linked to the gliadin fusion protein. When tTG is present, the tTG and recombinant deamidated gliadin are mixed together prior to immobilization to the solid phase.

Abstract: The present invention provides a method for determining whether a subject is suffering from celiac disease by contacting a sample of bodily fluid from the subject, with an antigen formed from a gliadin fusion protein immobilized on a solid support. The gliadin fusion protein of the antigen includes a recombinant deamidated gliadin linked to a tag such as Glutathione-S transferase (GST) protein. The antigen is prepared by immobilizing on the solid support the gliadin fusion protein via the tag. The antigen can further include tissue Transglutaminase (tTG) cross-linked to the gliadin fusion protein. When tTG is present, the tTG and recombinant deamidated gliadin are mixed together prior to immobilization to the solid phase.

Abstract: The present invention provides a method for determining whether a subject is suffering from celiac disease by contacting a sample of bodily fluid from the subject, with an antigen formed from a gliadin fusion protein immobilized on a solid support. The gliadin fusion protein of the antigen includes a recombinant deamidated gliadin linked to a tag such as Glutathione-S transferase (GST) protein. The antigen is prepared by immobilizing on the solid support the gliadin fusion protein via the tag. The antigen can further include tissue Transglutaminase (tTG) cross-linked to the gliadin fusion protein. When tTG is present, the tTG and recombinant deamidated gliadin are mixed together prior to immobilization to the solid phase.